Overview

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III

Status:
Not yet recruiting

Trial end date:
2025-05-31

Target enrollment:

Participant gender:

Summary

The study is to evaluate the efficacy of KL-A167 combined with cisplatin and gemcitabine vs placebo combined with cisplatin and gemcitabine in the treatment of recurrent or metastatic nasopharyngeal carcinoma, as measured by progression-free survival (PFS) per the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1

Phase:

Phase 3

Details

Lead Sponsor:

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Treatments:

Cisplatin
Gemcitabine